DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...

Global pharma and MedTech stocks rebound as U.S. President Donald Trump issues a 90-day pause on reciprocal tariffs for all ...